PDL Biopharma Operating Income

PDL Biopharma (PDLI) currently reports a operating income of $-60M as of September 2020. That compares with $-7.6M in the prior-year period — down 689.7% year over year. Use the charts on this page to explore PDL Biopharma's operating income history and peer comparisons.

PDL Biopharma's operating income decreased from $-7.6M to $-60M — a 689.7% year-over-year decrease (period ending September 2020). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

PDL Biopharma reported $-60M in operating income as of September 2020. That compares with $-7.6M in the prior-year period — down 689.7% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current operating income of $-60M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for PDL Biopharma, and consider following PDLI for alerts when major investors trade the stock.

PDL Biopharma is classified in the Healthcare sector. On operating income, it currently shows $-60M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing PDLI with unrelated industries.